| abstract |
Cancerous disease modifying antibodies (CDMAB) mediate killing of cancer cells to treat cancer. Antibodies generated in mice, upon immunization with metastatic ovarian cancer cells isolated from frozen human peritoneal fluid, are screened for cytotoxicity against a variety of cancer cells. An anti-cancer cytotoxic monoclonal antibody is isolated, produced by the hybπdoma AR102A317.8 deposited with IDAC as Accession Number 200208-01, which is cytotoxic to a breast cancer cell line and an ovarian cancer cell line, and reduces tumor burden in animal models of human breast and prostate cancer. The monoclonal antibody also binds to several cancer cell lines. This monoclonal antibody can be used to aid staging and diagnosis of cancer, and in the treatment of cancer. This cytotoxic monoclonal antibody can also be used to deliver toxms, enzymes, radioactive compounds and hematogenous cells to cancer cells, to further aid reduction of tumor burden. |